Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...
Hosted on MSN11mon
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's WhyCrispr stock is tumbling for the fifth straight week as the top Cathie Wood's holding struggles amid dimming expectations for its new Vertex-partnered gene-editing drug. Please watch the video at ...
Casgevy faces competition from BlueBird Bio’s Lyfgenia, priced at $3.1 million, 40% higher than Casgevy’s $2.2 million. Lyfgenia also carries a black box warning for blood cancer risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback